Recent progress in the diagnosis and treatment of primary vitreoretinal lymphoma

Min Zhou a, Gezhi Xu a, b, * 

a Department of Ophthalmology, Fudan University Eye and ENT Hospital, Fudan University, Shanghai, PR China 

b Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai, PR China

ARTICLE INFO

Article history:
Received 38 January 2016
Received in revised form 3 May 2016
Accepted 10 May 2016
Available online 27 June 2016

Keywords:
lymphoma 
primary 
retina 
vitreous

ABSTRACT

Primary vitreoretinal lymphoma (PVRL) was previously termed primary intraocular lymphoma. PVRL is a potentially fatal intraocular malignancy, and 65–90% of PVRL occurs in the central nervous system (CNS). The incidence of PVRL has been rising in both immunocompromised and immunocompetent populations worldwide. PVRL frequently masquerades as chronic uveitis. Advanced auxiliary examinations, such as optical coherence tomography and fundus autofluorescence have been applied in the diagnosis of PVRL. Histology and immunohistochemistry in combination with molecular tests and interleukin-10 analysis have been demonstrated as reliable in diagnosing PVRL. Despite early initiation of treatment, mortality is high with PVRL associated with CNS involvement and relapses are common. The use of systemic chemotherapy has not been proven to prevent CNS involvement; however, local therapies including intravitreal injections of methotrexate and/or rituximab and low-dose radiotherapy to the eye, has shown to be extremely effective in controlling intraocular lymphoma with encouraging results.

1. Introduction

Primary vitreoretinal lymphoma (PVRL) is a rare but potentially fatal intraocular malignancy,1–3 which is a subset of primary central nervous system lymphoma (PCNSL).4–10 

PVRL has been previously called primary intraocular lymphoma (PIOL).10,11 PIOL involving choroid was firstly mentioned in 1920 by Triebenstein14,15; however, in 1968 PIOL involving the retina described as “reticulum cell sarcoma” was reported by Vogel.14 In the early 1980s, associations between this disease and PCNSL were recognized13,15 and the origin of the tumor cells was demonstrated to be lymphoid cells (malignant B and T lymphocytes), not histiocyes.5,16,17 Thus the term “PIOL” was established.18 Recently, based on the World Health Organization classification of tumors, intraocular lymphoma represents a heterogeneous group of malignancies located in different tissues within the eye, each of which has different morphological, immunophenotypical, and genetic features, and completely different clinical courses.1,18 Since lymphomas originating from the retina/vitreous and the choroid are 

distinctive, PIOL can be classified as “PVRL” and “primary uveal lymphoma.” PVRL is proposed and defined as “a subset of PCNSL and a heterogeneous group of malignant lymphocytic neoplasms affecting the retina with or without involvement of the vitreous or the optic nerve, and without evidence of brain or cerebrospinal fluid (CSF) involvement.”4,17,19 Most intraocular lymphomas are PVRL, while ocular manifestation of systemic lymphomas occurs commonly in the uvea; however, primary uveal lymphoma is rarely reported.15,20 Approximately 15–25% of patients with PCNSL ultimately develop an ocular manifestation of their lymphoma.5,17 With a 30-fold increase in the incidence of PCNSL in recent times, similar changes of PVRL incidence has been noted worldwide.7,21

PVRL frequently masquerades as chronic uveitis and the complexity of sample management poses a challenge not only to the ophthalmologists, but also to the pathologists. PVRL is characterized by an aggressive clinical course, despite early initiation of aggressive treatment with chemotherapy and/or radiotherapy, high relapse rate, and CNS involvement, has a poor prognosis with a 1-year overall survival of 25–40%.3,22 Due to the diverse patient populations and rarity of this disease, there are no established standards for diagnosis and therapy of PVRL.4,12 Recent advances of clinical diagnosis and management for PVRL, such as optical coherence tomographic (OCT) and intravitreal injection of medications, have been achieved with encouraging results. These new

http://dx.doi.org/10.1016/j.tjo.2016.05.002
2211-5056 (C) 2016, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
methods may greatly improve our understanding and practice in controlling PVRL.1,3,20,21–26

2. Clinical presentations and image findings

PVRL is the most common intraocular lymphoma, usually of the B-cell type as diffuse large B-cell lymphoma originally invades intraocular tissues: the retina, vitreous, and/or optic nerve.1,16,18,27

2.1. Ocular clinical manifestations

Clinically, ocular involvement occurs bilaterally in 64–83% of cases.1 PVRL is usually a disease of adulthood with few cases in infants and teenagers.5,21,28 Vitreous floaters may be noticed by the patient long before PVRL is suspected, which is the main reason for patients without CNS involvement to visit the ophthalmologist.2,11,20,29,30 PVRL frequently masquerades as chronic uveitis.31

Mild anterior segment inflammation is usually observed using slit lamp examination.17,21,12–34 Pseudohypopyon is a rare presentation (Figure 1).12 Sheets and clusters of lymphoma cells confined to the vitreous cavity are the most common ocular findings.1,2,12,20,21,30 Lymphoma cells are homogeneous and larger than inflammatory cells and do not cluster with reactive cells resulting in an “aurora borealis” appearance from cells lining along the vitreous fibers.1 Vitreous haze is often striking, from mild to severe.35 However, visual acuity of PVRL patients can be at least better than expected.36 The typical creamy lesions with yellow-white infiltrate deep to the retina or retinal pigment epithelium (RPE) with various sizes (Figure 2A), since lymphoma cells migrate to the sub-RPE/pre-Bruch’s space.1,2,17 Islands of pigments floating on these deposits make the characteristic “leopard-spot” pigmentation.1,37 The distinctive solid detachments of the RPE with irregular yellow-white deposits are considered pathognomonic of PVRL.20 Exudative retinal detachment is present in severe PVRL cases. Spontaneous resolution is often seen with RPE atrophy and subretinal fibrosis. Optic nerve and orbital involvement are sporadically reported.14

2.2. Ocular imaging

In addition to a thorough clinical examination, more and more advanced auxiliary examinations such as spectral-domain OCT (SD-OCT) and fundus autofluorescence (FAF) have been increasingly used to aid in identifying PVRL cases.2,23

Figure 1. Pseudohypopyon in the right eye of a 62-year-old female patient diagnosed with primary vitreoretinal lymphoma through aqueous aspiration.

Figure 2. (A) Fundus photograph of the left eye of the patient presents typical yellow–white creamy lesions infiltrated deep into the retina or retinal pigment epithelium with various sizes. (B) Correlation with the optical coherence tomographic section through the yellow–white lesions shows multiple pre-Bruchs/subretinal pigment epithelium deposits that protrude anteriorly to the outer retina.

2.2.1. OCT

Recently, OCT has been reported to be helpful in the diagnosis of retinal abnormalities in PVRL.23 Lymphoma cells directly infiltrate the retina and proliferate focally in the pre-Bruch’s/sub-RPE space presenting a semiopaque grey spot in a fundus photograph that appear as nodular hyper-reflective infiltrations at the level of RPE on SD-OCT (Figure 2B).23,25 Nodular or band hyper-reflective spots were noted in 43% of PVRL eyes.21,28 RPE damage, disruption of the photoreceptor inner segment/outer segment junction, multiple hyper-reflective infiltrations in the inner retina, and exudative retinal detachment with subretinal hyporeflective fluid may be revealed by SD-OCT in severe PVRL. Cystoid macular edema is rarely reported.45 However, these hyper-reflective signals between the Bruch’s membrane and RPE need to be differentiated from those seen in age-related macular degeneration (AMD) or polyoidal choroidal vasculopathy.12,21 Dramatic resolution of the lymphoma deposits along Bruch’s membrane was seen on the OCT after intravitreal chemotherapy.20 This noninvasive method may be convenient for further surveillance of relapse or resolution of PVRL.

2.2.2. FAF

FAF assesses the function of the RPE by detecting the lipofuscin distribution in various retinal disorders such as AMD.38 Recently, FAF has been noted to detect the active status of PVRL. On FAF images, hypofluorescent areas suggest RPE atrophy or lymphoma cells above the RPE, and hyperfluorescent spots indicate the overlapping of PVRL and RPE cells (Figure 3).12,21,38 Blockage by mass lesion was also seen in 11% of eyes with PVRL.38 Hyper-autofluorescent spots on FAF may correlate with the hypofluorescent spots on fluorescein angiography (FA; 36%) and the nodular hyper-reflective spots on OCT (43%).38,40 This concordance was
observed in 62% of patients.38 Granular patterns on FAF were identified in various locations in the retina; however, this was not limited to visible tumor location. Remarkably, the corresponding changes from hyperautofluorescent spots to hypoautofluorescent spots in retinal lesions are seen after intravitreal methotrexate treatment.23,38

2.2.3. Fundus FA and indocyanine green angiography

The most common pattern on FA was hypoautofluorescent round spots with a “leopard-spot” appearance (43%), which is better appreciated on photographs enhanced with venous FA (Figure 4).21,25,36,37,41,42 In a study of 44 PVRL patients, punctate hyperfluorescent window defects were revealed in 55%, round hypofluorescent lesions in 34%, and vasculitis in 14%, although only 2% cystoid macular edema was found in this study.21,43 In another study of 53 PVRL patients, clusters of round stable hypofluorescent lesions on FA that corresponded to punctate whitish lesions in the fundus and round-clustered hypofluorescent lesions revealed scarce by indocyanine green angiography, warrants further biopsies for differential diagnosis of PVRL with a positive predictive value of 88.9% and negative predictive value of 85%.41

2.3. CNS features and neuro-imaging

At the time of diagnosis of PVRL, detectable CNS involvement is present in 16–34% of patients.1,19,43,44 CNS involvement may occur at any time of the disease course, especially in the late stage when widespread dissemination of PCNSL occurs in 7–8% of patients.44 Within a mean interval of 8–29 months, 42–92% of PVRL cases presented with intracranial lymphoma.45,46 Patients with CNS involvement can present with neurological symptoms depending on the tumor location in the brain.44 The common presenting symptom is personality change and new-onset seizures as an indicator of CNS involvement.42

Sixty-two percent of PVRL patients have CNS lesions, especially in relapsed patients.47 Therefore, use of contrast-enhanced magnetic resonance imaging every 3 months during the disease course after the definitive diagnosis to detect CNS involvement is imperative.1,32 Lymphoma lesions with discrete or diffuse borders can be identified, which are hypodense on T1-weighted and hyperdense on T2-weighted images.44 (Positron emission tomography/computed tomography has been used to identify not only CNS lesions, but also ocular activity.2,20

3. Diagnosis

3.1. Biopsy

Biopsy for the cytological assessment of suspected intraocular lymphoma is invaluable not only in confirming the diagnosis, but also in providing information of prognostic importance.34,46,49 However, lymphoma cells are fragile that easily undergo necrosis,
and systemic corticosteroid use for treating a presumed “uveitis” also may cause false negative results.46 The corticosteroid treatment must be discontinued as least 2 weeks before biopsy.21 Surgical intervention to obtain sufficient material includes pars planavitrectomy, chorioretinal biopsy, aqueous aspiration, and rarely diagnostic enucleation.49,50 Before biopsy, it is crucial for surgeons to contact the pathologist to ensure use of the correct containers and preservative solutions.1,50 If prolonged delays of transportation are anticipated, the samples should be placed in culture medium or a mild cytostatic, such as herpes-glutamic acid buffer mediated organic solvent protection effect fixation or CytoLyte, which provides superior preservation of cytomorphology and immunoreactivity.7,25

3.1. Vitreous and retina

Clinically, pars planavitrectomy is performed most for PVRL biopsy because its diagnostic yield is superior to that of vitreous aspirate.49 A 25-gauge transconjunctival sutureless vitrectomy is a safe and effective technique for the diagnosis of PVRL.25 The effect of different vitrectomy cut-rates on lymphoma cell viability and diagnostic yield was investigated and a cut rate of 600 cpm is recommended for PVRL diagnosis.25 Routinely, it is useful to obtain undiluted vitreous (1–2 mL) and diluted vitreous samples as much as possible after turning on the infusion.35,55 Retinal biopsy is seldom used clinically and retinal samples should be taken from the deeper part of the lesion, near the choriocapillaris where viable lymphoma cells are most likely to be found.49 Aqueous aspiration may be adequately used in special conditions, such as pseudohypopyon. However, more than one biopsy is often needed to make a confident diagnosis if hampered by paucicellular specimens mixed with necrotic lymphoma cells.17 A study of 12 patients found that 30% of PVRL cases had a previous false-negative biopsy.1,2

3.1.2. CSF biopsy

Despite a low cellular yield for diagnosis, CSF biopsy is highly recommended to identify atypical lymphoid cells, which spares the patient from further invasive diagnostic procedures.6,17

3.2. Cytology and histopathology

Cytopathological evaluation was performed by an experienced cytopathologist on the vitreous or aqueous specimen to identify morphological evidence of PVRL characterized by large (2–5 times the diameter of a small lymphocyte), atypical lymphoid cells with large, irregular nuclei, prominent nucleoli, scanty basophilic cytoplasm, and rare mitoses.35 Using either Giemsa or Diff-Quick staining is recommended to identify lymphoma cells.35 Smaller, round lymphocytes, macrophages, and polymorphonuclear lymphocytes presenting as a reactive inflammatory infiltrate may outnumber the malignant cells, which is often misread as evidence of inflammation.19 Histologically, according to World Health Organization classification, the majority of PVRL is a high-grade, malignant non-Hodgkin lymphoma, and can be subclassified in most cases as diffuse large B-cell lymphoma.1,20

3.3. Immunocytochemistry and flow cytometry

Monoclonality, either a B-cell population stain positively for B-cell markers (CD19, CD20, or CD22) with restricted expression of either κ or λ, or a T-cell population stain positively for T-cell markers (CD3, CD4), can support B or T cell PVRL.20 Concomitant expression of BCL6 and MUM1 has also been reported by Wallace et al.49 in five PVRL patients. Flow cytometry can analyze larger numbers of different cell surface markers simultaneously to differentiate uveitis from lymphoma. A ratio of κ:λ of >3 or <0.6 is useful as a marker for clonality.20

3.4. Molecular analysis of gene rearrangements

Molecular technique with microdissection and polymerase chain reaction to detect a clonally expanded population of lymphocytes is an important adjunct to diagnose PVRL.36 The immunoglobulin heavy chain (IgH; FR2, FR3, and/or CDR3 primers) and T-cell receptor (TCR) gene rearrangements (TCR-γ) provide a molecular diagnosis of B- and T-cell lymphoma, respectively.54 Without microdissection to select a relatively pure lymphoma cell population, molecular testing may be less sensitive and specific.54 Positive IgH gene rearrangements reached 80.6% in a Japanese study including 67 PIOL patients.31 One-hundred percent positive of either IgH or TCR gene rearrangements in a study of 114 PIOL patients was reported; however, sampling of too few cells from microdissection may result in a false-positive result.20,52

3.5. Other laboratory tests of PVRL

A high level of interleukin (IL)-10 produced by B-cell lymphomas, is a Th2 cytokine and linked to rapid disease progression. A high level of IL-6 is secreted by normal inflammatory cells.1,2 In 1995, Chan et al.55 first reported that high levels of vitreous IL-10 were detected in three B-cell PVRL patients. Recently, higher levels of IL-10 (mean values: 543.4 pg/mL) in PIOL patients than in uveitis (21.9 pg/mL) in aqueous humor was revealed in a study of 51 PIOL.45 IL-10–1082A allele is a risk factor for higher IL-10 levels in PVRL and higher IL-10 levels have been correlated with more aggressive disease.35 Currently, a ratio of IL-10:IL-6 greater than 1 in ocular fluid have become adjunctive and supportive biomarkers for the diagnosis and prognosis of PVRL, particularly the B-cell PVRL.1,20

3.6. Differential diagnosis of PVRL

Clinical manifestations of PVRL frequently masquerade as both infectious and noninfectious uveitis, such as tuberculosis, acute retinal necrosis syndrome, retinocchoroidal toxoplasmosis, sphyilitic retinitis, endophthalmitis, or idiopathic uveitis.7,13,31,53,57 Ocular degeneration diseases, such as AMD and polypoidal choroidal vasculopathy, need to be differentiated diagnosed due to similar OCT imaging. Metastasis and amelanotic melanoma must be identified from a PVRL cohort.21

4. Treatment

At present, the overall survival rate of PVRL is still quite low and mortality rates range between 9% and 81% in follow-up periods ranging from 12 months to 35 months, even though PVRLs are highly radiosensitive and chemosensitive.3,5,45,51,58 Because no standard therapy for PVRL has been established yet, a symposium on PVRL was organized by the International Primary CNS Lymphoma Collaborative Group in 2011, and the following therapeutic guidelines was recommended.1 A professional team of experts in ophthalmology, oncology (particularly neuro-oncology or hematologic oncologist), and pathology are essential for optimizing patient management.3

1. Without CNS or systemic involvement: local treatment (intravitreal methotrexate, intravitreal rituximab, or low-dose (30–35 Gy) stereotactic external beam radiotherapy to the eye with close follow up and ongoing collaboration between neurooncologists and ophthalmologists. If both eyes are involved,
systemic chemotherapy has been suggested in addition to intravitreal medications for bilateral PVRL.\textsuperscript{1,59}

2. Involves the CNS: a high-dose methotrexate based systemic therapy (possibly with systemic rituximab) was suggested in conjunction with local ocular therapy. If the patient has failed systemic therapy and does not meet the criteria for a more aggressive therapy such as autologous stem cell transplantation, whole brain radiotherapy in conjunction with ocular radiotherapy should be considered.

Another published recommendation from the British Neuro-Oncology Society (National Cancer Action Team Rare Tumor Guidelines, June 2011) differed from the International Primary CNS Lymphoma Collaborative Group that specify systemic chemotherapy with high-dose methotrexate followed by whole-globe irradiation for concurrent or ocular only patients and intravitreal methotrexate as an effective treatment option for isolated ocular recurrences.\textsuperscript{20}

In one retrospective study to investigate the function of prophylactic therapy, 17 PVRL patients treated for ocular only disease with chemotherapy and/or irradiation lived an average of 60 months after onset of ocular symptoms until death compared with 35 months for 14 patients treated only after CNS disease developed.\textsuperscript{59} Another study also demonstrated that prophylactic systemic chemotherapy did not inhibit the onset of CNS involvement in PVRL patients, but it significantly prolonged brain involvement.\textsuperscript{61}

4.1. Chemotherapy

The efficiency of high-dose methotrexate is demonstrated to produce a response rate of up to 72% when used alone and up to 94–100% in combinations.\textsuperscript{1,2,21} Combined intravitreal methotrexate and systemic high-dose methotrexate treatment has been reported effective in 19 PIOL patients that the 5-year overall survival rate reached 55.8%.\textsuperscript{62} Intensive chemotherapy with thiopeta, busulfan, and cyclophosphamide followed by hematopoietic stem cell rescue in relapsed PCNSL and PIOL improved the 5-year survival probability to 62% and obtained complete remission in 66 out of 79 patients.\textsuperscript{12,21} Cytarabine has also been used with variable success rates, especially intrathecal use combined with methotrexate for recurrent cases.\textsuperscript{63} However, a recent 17-Center European collaborative study found that systemic chemotherapy in isolated PVRL patients was not proven to prevent CNSL and was associated with more severe adverse effects, such as acute renal failure.\textsuperscript{7} Maculopathy without significantly affecting visual acuity is also reported to be associated with chemotherapy.\textsuperscript{21}

4.2. Radiotherapy

At present, low-dose (30–35 Gy) stereotactic external beam radiotherapy to the eye is recommended as local treatment for ocular only PVRL patients.\textsuperscript{1} No ocular relapse was reported in any of 12 patient received radiotherapy (30–35 Gy in 15 fractions) during a mean 19 months follow up.\textsuperscript{58} If PVRL patients concurrent with CNS involvement have failed systemic chemotherapy and also unavailable to aggressive therapy, whole brain and eye radiotherapy may be added. Currently, whether to use intravitreal chemotherapy or ocular radiation as first-line therapy is still controversial. The complication of whole brain radiation often induces a delayed neurotoxicity with decline in cognitive function, ataxia, and even death, whereas ocular complications were cataract, dry eye, and radiation retinopathy.\textsuperscript{58,63}

4.3. Ocular therapy

Besides radiotherapy to the eye, another two local treatments are intravitreal methotrexate and rituximab.\textsuperscript{1}

Figure 5. Fundus photographs of a 62-year-old male with primary vitreoretinal lymphoma confirmed using vitreous biopsy who received intravitreal methotrexate treatment. (A) Before treatment; (B) 2 months after treatment; (C) 6 months after treatment; (D) 1 year after treatment. Note the corresponding changes from the significant yellow–white lesion to retinal scar after successful intravitreal methotrexate treatment.
4.3. Intravitreal methotrexate

Intravitreal methotrexate therapy is extremely effective in inducing clinical remission of vitreoretinal involvement in PVRL with acceptable morbidity (Figure 5). In a 10-year study using intravitreal injections of methotrexate as first line treatment in PVRL, none of the total 26 patients had an intraocular recurrence.20 Twenty injections of 0.4 mg/0.1 mL-methotrexate intravitreals are performed twice weekly for 4 weeks, once weekly for 8 weeks, and then monthly for 9 months (total of 25 injections). Remission was observed after a mean of 6.4 injections. The common complications were transient intraocular pressure elevations and corneal epitheliopathy which subsided when the interval between injections increased.2,3

4.3.2. Intravitreal rituximab

Intravitreal injections of rituximab, an anti-CD20 monoclonal antibody, have been used recently to treat CD20-positive PVRL.61 Twenty eyes with CD20-positive PVRL discontinued intravitreal methotrexate because of severe corneal epitheliopathy, and received weekly intravitreal injections of 1 mg/0.1 mL-rituximab for 4 weeks as a one-course protocol with encouraging results.64 However, half recurrence was present in this study. Rituximab may be a less toxic alternative to methotrexate.

5. Conclusions

Currently, diagnostic and therapeutic dilemmas of PVRL still frequently occur in clinical practice. High relapse rates and CNS involvement are common, which result in poor prognosis of PVRL. High relapse rates and CNS involvement are common, which result in poor prognosis of PVRL. Half recurrence was present in this study. Rituximab may be a less toxic alternative to methotrexate.

Acknowledgments

Publication of this article was supported in part by research grants from the National Natural Science Foundation of China (81570854) and the National Key Basic Research Program of China (2013CB967503).

References

1. Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist. 2011;16:1589–1599.
2. Chan CC, Sen HN. Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma. Discov Med. 2013;15:93–100.
3. Remens A, Bromberg J, Touitou V, et al. Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study. JAMA Ophthalmol. 2015;133:191–197.
4. Mason JO, Fischer DH. Intrachoroidal chemotherapy for recurrent central nervous system intraocular lymphoma. Ophthalmol. 2003;110:1241–1244.
5. Coupland SE, Hummel M, Muller HH, Stein H. Molecular analysis of immunoglobulin genes in primary intraocular lymphoma. Invest Ophthalmol Vis Sci. 2005;46:3507–3514.
6. Mochizuki M, Singh AD. Epidemiology and clinical features of intraocular lymphoma. Ocul Immunol Inflamm. 2009;17:99–72.
7. Schubert M. Epidemiology of primary CNS lymphoma. J Neurolonc. 1999;43:195–201.
8. Char DH, Ljung BM, Miller T, Phillips T. Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management. Ophthalmol. 1988;95:625–630.
9. Larkin KL, Saboo US, Comer GM, et al. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma. Br J Ophthalmol. 2014;98:99–103.
10. Hong JT, Chao JR, Lee CY, et al. Optic disc involvement in patients with primary CNS lymphoma. J Neurolonc. 2011;102:139–145.
11. Quamel SJ, Mendelsohn G, Mann RB, Green WR. Intraocular lymphomas. Natural history based on a clinicopathologic study of eight cases and review of the literature. Cancer. 1968;21:853–866.
12. Mulay K, Narula R, Honavar SG. Primary vitreoretinal lymphoma. Indian J Ophthalmol. 2015;63:180–186.
13. Triebenstein D. Ein Beitrag zur frage der aleukämischen augenveränderungen. Klin Monatbl Augenheilkd. 1920;64:825–836.
14. Vogel MH, Font RL, Zimmerman LE, Levine RA. Reticulum cell sarcoma of the retina and uvea. Report of six cases and review of the literature. Am J Ophthalmol. 1968;66:205–215.
15. Char DH, Margolis L, Newman AB. Ocular reticulum cell sarcoma. Am J Ophthalmol. 1981;91:480–483.
16. Chan CC. Molecular pathology of primary intraocular lymphoma. Trans Am Ophthalmol Soc. 2003;101:275–292.
17. Coupland SE, Chan CC, Smith J. Pathophysiology of retinal lymphoma. Ocul Immunol Inflamm. 2009;17:227–237.
18. Char DH, Ljung BM, Deschennes J, Miller TR. Intraocular lymphoma: immunological and cytological analysis. Br J Ophthalmol. 1988;72:905–911.
19. Coupland SE, Heimann H, Bechakas NE. Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol. 2004;242:901–913.
20. Davis JL. Intraocular lymphoma: a clinical perspective. Eye (Lond). 2013;27:151–162.
21. Sagoo MS, Mehta H, Swapnillai AJ, et al. Primary intraocular lymphoma. Surv Ophthalmol. 2014;59:503–516.
22. Sierra Del Rio M, Ricard D, Houillier C, et al. Prophylactic intravitreal chemotherapy in primary CNS lymphoma. J Neurolonc. 2012;106:143–146.
23. Egeawa M, Mitamura Y, Hayashi Y, Naito T. Spectral-domain optical coherence tomography and fundus autofluorescence findings in eyes with primary intraocular lymphoma. Clin Ophthalmol. 2014;8:335–341.
24. Mudhar HS, Sheard R. Diagnostic cellular yield is superior with full pars plana vitrectomy compared with core vitreous biopsy. Eye (Lond). 2013;27:59–55.
25. Jang HS, Sepah YJ, Sophr R, et al. Longitudinal spectral domain optical coherence tomography changes in eyes with intraocular lymphoma. J Ophthalmic Inflamm Infect. 2013;3:59.
26. Frenkel S, Hendler K, Siegal T, Shalom E, Pe’er J. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2009;92:383–388.
27. Chan CC. Primary intraocular lymphoma: clinical features, diagnosis, and treatment. Clin Ophthalmol. 2003;4:30–31.
28. Wender A, Adar A, Mao E, Yassur Y. Primary B-cell lymphoma of the eyes and brain in a 3-year-old boy. Arch Pathol Lab Med. 1994;118:1292–1295.
29. Turaka K, Bryan JS, De Souza S, et al. Vitreoretinal lymphoma: changing trends in diagnosis and local treatment modalities at a single institution. Clin Lymphoma Myeloma Leuk. 2012;12:412–417.
30. Levy-Citré CA, Chan CC, Nussblatt RB. Diagnosis and management of primary intraocular lymphoma. Hematol Oncol Clin North Am. 2005;19:739–749, viii.
31. SM MK, Jamplol LM. Variations in the presentation of primary intraocular lymphoma: case reports and a review. Surv Ophthalmol. 2001;45:463–471.
32. Sen HN, Bodaghi B, Hoang PL, Nussblatt R. Primary intraocular lymphoma: diagnosis and differential diagnosis. Ocul Immunol Inflamm. 2009;17:133–141.
33. Kimura K, Usui Y, Goto H. Japanese Intraocular Lymphoma Study G. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn J Ophthalmol. 2012;56:383–389.
34. Chan CC, Fission S, Bodaghi B. The future of primary intraocular lymphoma (retinal lymphoma). Ocul Immunol Inflamm. 2005;13:375–379.
35. Faia U, Chan CC. Primary intraocular lymphoma. Arch Pathol Lab Med. 2009;133:1228–1232.
36. Whitcup SM, de Smet MD, Rubin B, et al. Intraocular lymphoma. Clinical and histopathologic diagnosis. Ophthalmology. 1993;100:1399–1406.
37. Davis JL. Diagnosis of intraocular lymphoma. Ocul Immunol Inflamm. 2004;12:7–16.
38. Casady M, Faia L, Nazemzadeh M, Nussblatt R, Chan CC, Sen HN. Fundus autofluorescence patterns in primary intraocular lymphoma. Retina. 2014;34:366–372.
39. Jiang T, Zhao Z, Chang Q. Evaluation of cytologic specimens obtained during experimental vitreous biopsy using B-cell line. Eur J Ophthalmol. 2014;24:911–917.
40. Iishi T, Ohno-Matsui K, Kaneko Y, et al. Fundus autofluorescence patterns in eyes with primary intraocular lymphoma. Retina. 2010;30:23–32.
41. Fardeau C, Lee CF, Merle-Beral H, et al. Retinal fluorescence, indocyanine green angiography, and optic coherence tomography in non-Hodgkin primary intraocular lymphoma. Am J Ophthalmol. 2009;147:886–894.
42. Velez G, Chan CC, Csaky KG. Fluorescein angiographic findings in primary intraocular lymphoma. Retina. 2002;22:37–43.
43. Casady M, Giron A, Bodaghi B, et al. IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma. Invest Ophthalmol Vis Sci. 2007;48:3253–3259.
44. Herrlinger U. Primary CNS lymphomas: findings outside the brain. J Neurolonc. 1999;43:227–230.
45. Akpek EK, Ahmed I, Hochberg FH, et al. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. *Ophthalmology*. 1999;106:1805–1810.

46. Peterson K, Gordon KB, Heinemann MH, DeAngelis LM. The clinical spectrum of ocular lymphoma. *Cancer*. 1993;72:843–849.

47. Grimm SA, Pulido JS, Jahnke K, et al. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. *Ann Oncol*. 2007;18:1851–1855.

48. Wallace DJ, Shen D, Reed GF, et al. Detection of the bcl-2 t(14;18) translocation and proto-oncogene expression in primary intraocular lymphoma. *Invest Ophthalmol Vis Sci*. 2006;47:2750–2756.

49. Gonzales JA, Chan CC. Biopsy techniques and yields in diagnosing primary intraocular lymphoma. *Int Ophthalmol*. 2007;27:241–250.

50. Yeh S, Weinbl ED, Faia LJ, et al. 25-Gauge transconjunctival sutureless vitrectomy for the diagnosis of intraocular lymphoma. *Br J Ophthalmol*. 2010;94:633–638.

51. Coupland SE, Damato B. Understanding intraocular lymphomas. *Clin Experiment Ophthalmol*. 2008;36:564–578.

52. Wang Y, Shen D, Wang YM, Sen HN, Chan CC. Molecular biomarkers for the diagnosis of primary vitreoretinal lymphoma. *Int J Mol Sci*. 2011;12:5684–5697.

53. White VA, Gascoyne RD, Paton KE. Use of the polymerase chain reaction to detect B- and T-cell gene rearrangements in vitreous specimens from patients with intraocular lymphoma. *Arch Ophthalmol*. 1999;117:761–765.

54. Shen DF, Zhuang Z, LeHoang P, et al. Utility of microdissection and polymerase chain reaction for the detection of immunoglobulin gene rearrangement and translocation in primary intraocular lymphoma. *Ophthalmology*. 1998;105:1664–1669.

55. Chan CC, Whitcup SM, Solomon D, Nussenblatt RB. Interleukin-10 in the vitreous of patients with primary intraocular lymphoma. *Am J Ophthalmol*. 1995;120:671–673.

56. Ramkumar HL, Shen de F, Tuo J, et al. IL-10-1082 SNP and IL-10 in primary CNS and vitreoretinal lymphomas. *Graefes Arch Clin Exp Ophthalmol*. 2012;250:1541–1548.

57. Pahk PJ, Todd DJ, Blaha GR, et al. Intravascular lymphoma masquerading as Vogt-Koyanagi-Harada syndrome. *Ocul Immunol Inflamm*. 2008;16:123–126.

58. Berenboom A, Davila RM, Lin HS, Harbour JW. Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. *Eye (Lond)*. 2007;21:1198–1201.

59. Pe’er J, Hochberg FH, Foster CS. Clinical review: treatment of vitreoretinal lymphoma. *Ocul Immunol Inflamm*. 2009;17:299–306.

60. Hormigo A, Abrey L, Heinemann MH, DeAngelis LM. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. *Br J Haematol*. 2004;126:202–208.

61. Hashida N, Ohguro N, Nishida K. Efficacy and complications of intravitreal rituximab injection for treating primary vitreoretinal lymphoma. *Transl Vis Sci Technol*. 2012;1:1.

62. Ma WL, Hou HA, Hsu YJ, et al. Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection. *Ann Hematol*. 2016;95:593–601.

63. Rosenfeld MR, Pruett AA. Management of malignant gliomas and primary CNS lymphoma: standard of care and future directions. *Continuum*. 2012;18:406–415.

64. Hashida N, Nakai K, Saitoh N, Nishida K. Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma. *Graefes Arch Clin Exp Ophthalmol*. 2014;252:687–693.